Higher mortality risk from lung and hematological neoplasms in patients with rheumatoid arthritis: An observational study from the Spanish National Registry.

IF 2.6 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Medicina Clinica Pub Date : 2024-11-06 DOI:10.1016/j.medcli.2024.09.007

Jorge Esteban-Sampedro, Víctor Moreno-Torres, Mario Martín-Portugués

{"title":"Higher mortality risk from lung and hematological neoplasms in patients with rheumatoid arthritis: An observational study from the Spanish National Registry.","authors":"Jorge Esteban-Sampedro, Víctor Moreno-Torres, Mario Martín-Portugués","doi":"10.1016/j.medcli.2024.09.007","DOIUrl":null,"url":null,"abstract":"Objective: Evaluating the impact of solid organ neoplasms (SON) and hematological neoplasms (HN) on mortality among RA patients in a nationwide study.Methods: A retrospective, observational comparison of SON and HN-related deaths in RA patients and the general Spanish population was conducted (Spanish Hospital Discharge Database). Binary logistic regression analyzed the impact of RA on mortality risk from each neoplasm.Results: From 2016 to 2019, 139,531 neoplasm-related deaths were recorded, including 813 (0.6%) from RA patients. Patients with RA presented a lower mortality rate from SON (85.1% vs 91.2%, OR 0.99), mainly due to colorectal carcinoma (8% vs 10.6%, OR 0.67) and hepatocarcinoma (1% vs 2.7%, OR 0.44), but higher lung neoplasms risk (20.2% vs 18.6%, OR 1.31). HN-related deaths were also more prevalent in RA patients (14.9% vs 8.8%, OR 1.73), especially B and T/NK non-Hodgkin's lymphoma (6% vs 2.8%, OR 2.12) and myeloid leukemia (4.4% vs 2.3%, OR 1.92).Conclusion: RA patients might have a higher mortality risk from lung and hematologic neoplasms. Reducing immunosuppressive burden and developing early-detection programs should be primary goals in this population.","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Clinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.medcli.2024.09.007","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Evaluating the impact of solid organ neoplasms (SON) and hematological neoplasms (HN) on mortality among RA patients in a nationwide study.

Methods: A retrospective, observational comparison of SON and HN-related deaths in RA patients and the general Spanish population was conducted (Spanish Hospital Discharge Database). Binary logistic regression analyzed the impact of RA on mortality risk from each neoplasm.

Results: From 2016 to 2019, 139,531 neoplasm-related deaths were recorded, including 813 (0.6%) from RA patients. Patients with RA presented a lower mortality rate from SON (85.1% vs 91.2%, OR 0.99), mainly due to colorectal carcinoma (8% vs 10.6%, OR 0.67) and hepatocarcinoma (1% vs 2.7%, OR 0.44), but higher lung neoplasms risk (20.2% vs 18.6%, OR 1.31). HN-related deaths were also more prevalent in RA patients (14.9% vs 8.8%, OR 1.73), especially B and T/NK non-Hodgkin's lymphoma (6% vs 2.8%, OR 2.12) and myeloid leukemia (4.4% vs 2.3%, OR 1.92).

Conclusion: RA patients might have a higher mortality risk from lung and hematologic neoplasms. Reducing immunosuppressive burden and developing early-detection programs should be primary goals in this population.

查看原文本刊更多论文

类风湿性关节炎患者死于肺部和血液肿瘤的风险更高：西班牙国家登记处的一项观察性研究。

摘要在一项全国性研究中评估实体器官肿瘤（SON）和血液肿瘤（HN）对RA患者死亡率的影响：对RA患者和西班牙一般人群中与SON和HN相关的死亡进行了回顾性观察比较（西班牙出院数据库）。二元逻辑回归分析了RA对每种肿瘤死亡风险的影响：从2016年到2019年，共记录了139531例肿瘤相关死亡，其中813例（0.6%）来自RA患者。RA患者的SON死亡率较低（85.1% vs 91.2%，OR 0.99），主要是结直肠癌（8% vs 10.6%，OR 0.67）和肝癌（1% vs 2.7%，OR 0.44），但肺部肿瘤风险较高（20.2% vs 18.6%，OR 1.31）。与 HN 相关的死亡在 RA 患者中也更常见（14.9% vs 8.8%，OR 1.73），尤其是 B 型和 T/NK 型非霍奇金淋巴瘤（6% vs 2.8%，OR 2.12）和骨髓性白血病（4.4% vs 2.3%，OR 1.92）：结论：RA患者死于肺癌和血液肿瘤的风险可能更高。结论：RA 患者罹患肺癌和血液肿瘤的死亡风险较高，减少免疫抑制负担和制定早期检测计划应成为这类人群的首要目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicina Clinica 医学-医学：内科

CiteScore

3.10

自引率

5.10%

发文量

295

审稿时长

22 days

期刊介绍： Medicina Clínica, fundada en 1943, es una publicación quincenal dedicada a la promoción de la investigación y de la práctica clínica entre los especialistas de la medicina interna, así como otras especialidades. Son características fundamentales de esta publicación el rigor científico y metodológico de sus artículos, la actualidad de los temas y, sobre todo, su sentido práctico, buscando siempre que la información sea de la mayor utilidad en la práctica clínica.